Table of Contents Author Guidelines Submit a Manuscript
Advances in Medicine
Volume 2015, Article ID 907267, 10 pages
http://dx.doi.org/10.1155/2015/907267
Review Article

Mathematical Modelling and Tuberculosis: Advances in Diagnostics and Novel Therapies

Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA

Received 5 June 2014; Revised 18 February 2015; Accepted 26 February 2015

Academic Editor: Aliya Naheed

Copyright © 2015 Alice Zwerling et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. McNerney, M. Maeurer, I. Abubakar et al., “Tuberculosis diagnostics and biomarkers: needs, challenges, recent advances, and opportunities,” Journal of Infectious Diseases, vol. 205, supplement 2, pp. S147–S158, 2012. View at Publisher · View at Google Scholar · View at Scopus
  2. C. C. Boehme, S. Saacks, and R. J. O'Brien, “The changing landscape of diagnostic services for tuberculosis,” Seminars in Respiratory and Critical Care Medicine, vol. 34, no. 1, pp. 17–31, 2013. View at Publisher · View at Google Scholar · View at Scopus
  3. TB Alliance, Confronting TB: What It Takes, Global Report 2008, TB Alliance, New York, NY, USA, 2008.
  4. A. Y. Sun, M. Pai, H. Salje, S. Satyanarayana, S. Deo, and D. W. Dowdy, “Modeling the impact of alternative strategies for rapid molecular diagnosis of tuberculosis in Southeast Asia,” The American Journal of Epidemiology, vol. 178, no. 12, pp. 1740–1749, 2013. View at Publisher · View at Google Scholar · View at Scopus
  5. M. O. Fofana, G. M. Knight, G. B. Gomez, R. G. White, and D. W. Dowdy, “Population-level impact of shorter-course regimens for tuberculosis: a model-based analysis,” PLoS ONE, vol. 9, no. 5, Article ID e96389, 2014. View at Publisher · View at Google Scholar · View at Scopus
  6. D. W. Dowdy, I. Lotia, A. S. Azman, J. Creswell, S. Sahu, and A. J. Khan, “Population-level impact of active tuberculosis case finding in an Asian megacity,” PLoS ONE, vol. 8, no. 10, Article ID e77517, 2013. View at Publisher · View at Google Scholar · View at Scopus
  7. D. W. Dowdy, S. Basu, and J. R. Andrews, “Is passive diagnosis enough? The impact of subclinical disease on diagnostic strategies for tuberculosis,” American Journal of Respiratory and Critical Care Medicine, vol. 187, no. 5, pp. 543–551, 2013. View at Publisher · View at Google Scholar · View at Scopus
  8. C. M. Denkinger, M. Pai, and D. W. Dowdy, “Do we need to detect isoniazid resistance in addition to rifampicin resistance in diagnostic tests for tuberculosis?” PLoS ONE, vol. 9, no. 1, Article ID e84197, 2014. View at Publisher · View at Google Scholar · View at Scopus
  9. T. Cohen, C. Colijn, B. Finklea, and M. Murray, “Exogenous re-infection and the dynamics of tuberculosis epidemics: local effects in a network model of transmission,” Journal of the Royal Society Interface, vol. 4, no. 14, pp. 523–531, 2007. View at Publisher · View at Google Scholar · View at Scopus
  10. P. Kasaie, J. R. Andrews, W. D. Kelton, and D. W. Dowdy, “Timing of tuberculosis transmission and the impact of household contact tracing: an agent-based simulation model,” The American Journal of Respiratory and Critical Care Medicine, vol. 189, no. 7, pp. 845–852, 2014. View at Publisher · View at Google Scholar · View at Scopus
  11. M. Murray, “Determinants of cluster distribution in the molecular epidemiology of tuberculosis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 3, pp. 1538–1543, 2002. View at Publisher · View at Google Scholar · View at Scopus
  12. R. Anderson, R. May, and B. Anderson, Infectious Diseases of Humans: Dynamics and Control, Oxford Science Publications, 1991.
  13. M. J. Keeling and P. Rohani, Modeling Infectious Diseases in Humans and Animals, Princeton University Press, Princeton, NJ, USA, 2007. View at MathSciNet
  14. N. A. Menzies, T. Cohen, H.-H. Lin, M. Murray, and J. A. Salomon, “Population health impact and cost-effectiveness of tuberculosis diagnosis with Xpert MTB/RIF: a dynamic simulation and economic evaluation,” PLoS Medicine, vol. 9, no. 11, Article ID e1001347, 2012. View at Publisher · View at Google Scholar · View at Scopus
  15. M. Pai, C. M. Denkinger, S. V. Kik et al., “Gamma interferon release assays for detection of Mycobacterium tuberculosis infection,” Clinical Microbiology Reviews, vol. 27, no. 1, pp. 3–20, 2014. View at Publisher · View at Google Scholar · View at Scopus
  16. S. D. Lawn, “Diagnosis of pulmonary tuberculosis,” Current Opinion in Pulmonary Medicine, vol. 19, no. 3, pp. 280–288, 2013. View at Publisher · View at Google Scholar · View at Scopus
  17. A. S. Dharmadhikari and E. A. Nardell, “What animal models teach humans about tuberculosis,” American Journal of Respiratory Cell and Molecular Biology, vol. 39, no. 5, pp. 503–508, 2008. View at Publisher · View at Google Scholar · View at Scopus
  18. G. Delogu and D. Goletti, “The spectrum of tuberculosis infection: new perspectives in the era of biologics,” Journal of Rheumatology, vol. 41, no. 91, pp. 11–16, 2014. View at Publisher · View at Google Scholar · View at Scopus
  19. D. Dowdy, C. Dye, and T. Cohen, “Data needs for evidence-based decisions: a tuberculosis modeler's ‘wish list’,” International Journal of Tuberculosis and Lung Disease, vol. 17, no. 7, pp. 866–877, 2013. View at Publisher · View at Google Scholar · View at Scopus
  20. E. A. Nardell, “Catching droplet nuclei: toward a better understanding of tuberculosis transmission,” American Journal of Respiratory and Critical Care Medicine, vol. 169, no. 5, pp. 553–554, 2004. View at Publisher · View at Google Scholar · View at Scopus
  21. A. Tostmann, S. V. Kik, N. A. Kalisvaart et al., “Tuberculosis transmission by patients with smear-negative pulmonary tuberculosis in a large cohort in the Netherlands,” Clinical Infectious Diseases, vol. 47, no. 9, pp. 1135–1142, 2008. View at Publisher · View at Google Scholar · View at Scopus
  22. J. M. Bryant, S. R. Harris, J. Parkhill et al., “Whole-genome sequencing to establish relapse or re-infection with Mycobacterium tuberculosis: a retrospective observational study,” The Lancet Respiratory Medicine, vol. 1, no. 10, pp. 786–792, 2013. View at Publisher · View at Google Scholar · View at Scopus
  23. J. M. Bryant, D. M. Grogono, D. Greaves et al., “Whole-genome sequencing to identify transmission of Mycobacterium abscessus between patients with cystic fibrosis: a retrospective cohort study,” The Lancet, vol. 381, no. 9877, pp. 1551–1560, 2013. View at Publisher · View at Google Scholar · View at Scopus
  24. T. M. Walker, C. L. C. Ip, R. H. Harrell et al., “Whole-genome sequencing to delineate Mycobacterium tuberculosis outbreaks: a retrospective observational study,” The Lancet Infectious Diseases, vol. 13, no. 2, pp. 137–146, 2013. View at Publisher · View at Google Scholar · View at Scopus
  25. A. Roetzer, R. Diel, T. A. Kohl et al., “Whole genome sequencing versus traditional genotyping for investigation of a Mycobacterium tuberculosis outbreak: a longitudinal molecular epidemiological study,” PLoS Medicine, vol. 10, no. 2, Article ID e1001387, 2013. View at Publisher · View at Google Scholar · View at Scopus
  26. M. Beisiegel, H.-J. Mollenkopf, K. Hahnke et al., “Combination of host susceptibility and Mycobacterium tuberculosis virulence define gene expression profile in the host,” European Journal of Immunology, vol. 39, no. 12, pp. 3369–3384, 2009. View at Publisher · View at Google Scholar · View at Scopus
  27. M. Beisiegel, M. Kursar, M. Koch et al., “Combination of host susceptibility and virulence of mycobacterium tuberculosis determines dual role of nitric oxide in the protection and control of inflammation,” Journal of Infectious Diseases, vol. 199, no. 8, pp. 1222–1232, 2009. View at Publisher · View at Google Scholar · View at Scopus
  28. P. D. O. Davies and J. M. Grange, “Factors affecting susceptibility and resistance to tuberculosis,” Thorax, vol. 56, supplement 2, pp. ii23–ii29, 2001. View at Google Scholar · View at Scopus
  29. E. L. Corbett, C. J. Watt, N. Walker et al., “The growing burden of tuberculosis: global trends and interactions with the HIV epidemic,” Archives of Internal Medicine, vol. 163, no. 9, pp. 1009–1021, 2003. View at Publisher · View at Google Scholar · View at Scopus
  30. M. A. Sanchez and S. M. Blower, “Uncertainty and sensitivity analysis of the basic reproductive rate: tuberculosis as an example,” American Journal of Epidemiology, vol. 145, no. 12, pp. 1127–1137, 1997. View at Publisher · View at Google Scholar · View at Scopus
  31. C. C. Boehme, P. Nabeta, D. Hillemann et al., “Rapid molecular detection of tuberculosis and rifampin resistance,” The New England Journal of Medicine, vol. 363, no. 11, pp. 1005–1015, 2010. View at Publisher · View at Google Scholar · View at Scopus
  32. H.-H. Lin, I. Langley, R. Mwenda et al., “A modelling framework to support the selection and implementation of new tuberculosis diagnostic tools,” International Journal of Tuberculosis and Lung Disease, vol. 15, no. 8, pp. 996–1004, 2011. View at Publisher · View at Google Scholar · View at Scopus
  33. H.-H. Lin, D. Dowdy, C. Dye, M. Murray, and T. Cohen, “The impact of new tuberculosis diagnostics on transmission: why context matters,” Bulletin of the World Health Organization, vol. 90, pp. 739–747, 2012. View at Google Scholar · View at Scopus
  34. S. Keshavjee and P. E. Farmer, “Tuberculosis, drug resistance, and the history of modern medicine,” The New England Journal of Medicine, vol. 367, no. 10, pp. 931–936, 2012. View at Publisher · View at Google Scholar · View at Scopus
  35. C. Lienhardt, M. Raviglione, M. Spigelman et al., “New drugs for the treatment of tuberculosis: needs, challenges, promise, and prospects for the future,” Journal of Infectious Diseases, vol. 205, supplement 2, pp. S241–S249, 2012. View at Publisher · View at Google Scholar · View at Scopus
  36. World Health Organization (WHO), STOP TB: Working Group on New TB Drugs Pipeline of TB Drugs, World Health Organization (WHO), Geneva, Switzerland, 2014, http://www.newtbdrugs.org/pipeline.php.
  37. K. E. Dooley, E. L. Nuermberger, and A. H. Diacon, “Pipeline of drugs for related diseases: tuberculosis,” Current Opinion in HIV and AIDS, vol. 8, no. 6, pp. 579–585, 2013. View at Publisher · View at Google Scholar · View at Scopus
  38. E. W. Orenstein, S. Basu, N. S. Shah et al., “Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis,” The Lancet Infectious Diseases, vol. 9, no. 3, pp. 153–161, 2009. View at Publisher · View at Google Scholar · View at Scopus
  39. J. S. Mukherjee, M. L. Rich, A. R. Socci et al., “Programmes and principles in treatment of multidrug-resistant tuberculosis,” The Lancet, vol. 363, no. 9407, pp. 474–481, 2004. View at Publisher · View at Google Scholar · View at Scopus
  40. N. R. Gandhi, P. Nunn, K. Dheda et al., “Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis,” The Lancet, vol. 375, no. 9728, pp. 1830–1843, 2010. View at Publisher · View at Google Scholar · View at Scopus
  41. M. Lipsitch and B. R. Levin, “Population dynamics of tuberculosis treatment: mathematical models of the roles of non-compliance and bacterial heterogeneity in the evolution of drug resistance,” International Journal of Tuberculosis and Lung Disease, vol. 2, no. 3, pp. 187–199, 1998. View at Google Scholar · View at Scopus
  42. B. R. Levin, M. Lipsitch, V. Perrot et al., “The population genetics of antibiotic resistance,” Clinical Infectious Diseases, vol. 24, supplement 1, pp. S9–S16, 1997. View at Google Scholar · View at Scopus
  43. C. Dye, B. G. Williams, M. A. Espinal, and M. C. Raviglione, “Erasing the world's slow stain: strategies to beat multidrug-resistant tuberculosis,” Science, vol. 295, no. 5562, pp. 2042–2046, 2002. View at Publisher · View at Google Scholar · View at Scopus
  44. C. Dye and M. A. Espinal, “Will tuberculosis become resistant to all antibiotics?” Proceedings of the Royal Society B: Biological Sciences, vol. 268, no. 1462, pp. 45–52, 2001. View at Publisher · View at Google Scholar · View at Scopus
  45. T. Cohen, C. Dye, C. Colijn, B. Williams, and M. Murray, “Mathematical models of the epidemiology and control of drug-resistant TB,” Expert Review of Respiratory Medicine, vol. 3, no. 1, pp. 67–79, 2009. View at Publisher · View at Google Scholar · View at Scopus
  46. S. M. Blower, P. M. Small, and P. C. Hopewell, “Control strategies for tuberculosis epidemics: new models for old problems,” Science, vol. 273, no. 5274, pp. 497–500, 1996. View at Publisher · View at Google Scholar · View at Scopus
  47. B. Müller, S. Borrell, G. Rose, and S. Gagneux, “The heterogeneous evolution of multidrug-resistant Mycobacterium tuberculosis,” Trends in Genetics, vol. 29, no. 3, pp. 160–169, 2013. View at Publisher · View at Google Scholar · View at Scopus
  48. M. Zignol, W. van Gemert, D. Falzon et al., “Surveillance of anti-tuberculosis drug resistance in the world: an updated analysis, 2007–2010,” Bulletin of the World Health Organization, vol. 90, no. 2, pp. 111D–119D, 2012. View at Publisher · View at Google Scholar · View at Scopus
  49. J. G. Pasipanodya and T. Gumbo, “A new evolutionary and pharmacokinetic-pharmacodynamic scenario for rapid emergence of resistance to single and multiple anti-tuberculosis drugs,” Current Opinion in Pharmacology, vol. 11, no. 5, pp. 457–463, 2011. View at Publisher · View at Google Scholar · View at Scopus
  50. D. Laurenzo and S. A. Mousa, “Mechanisms of drug resistance in Mycobacterium tuberculosis and current status of rapid molecular diagnostic testing,” Acta Tropica, vol. 119, no. 1, pp. 5–10, 2011. View at Publisher · View at Google Scholar · View at Scopus
  51. M. Coscolla and S. Gagneux, “Does M. tuberculosis genomic diversity explain disease diversity?” Drug Discovery Today: Disease Mechanisms, vol. 7, no. 1, pp. e43–e59, 2010. View at Publisher · View at Google Scholar · View at Scopus
  52. S. Borrell and S. Gagneux, “Strain diversity, epistasis and the evolution of drug resistance in Mycobacterium tuberculosis,” Clinical Microbiology and Infection, vol. 17, no. 6, pp. 815–820, 2011. View at Publisher · View at Google Scholar · View at Scopus
  53. N. R. Gandhi, A. Moll, A. W. Sturm et al., “Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa,” The Lancet, vol. 368, no. 9547, pp. 1575–1580, 2006. View at Publisher · View at Google Scholar · View at Scopus
  54. S. M. Blower, A. R. McLean, T. C. Porco et al., “The intrinsic transmission dynamics of tuberculosis epidemics,” Nature Medicine, vol. 1, no. 8, pp. 815–821, 1995. View at Publisher · View at Google Scholar · View at Scopus
  55. S. Shrestha, G. M. Knight, M. Fofana et al., “Drivers and trajectories of resistance to new first-line drug regimens for tuberculosis,” Open Forum Infectious Diseases, vol. 1, 2014. View at Publisher · View at Google Scholar
  56. R. J. F. Ypma, H. K. Altes, D. van Soolingen, J. Wallinga, and W. M. van Ballegooijen, “A sign of superspreading in tuberculosis: highly skewed distribution of genotypic cluster sizes,” Epidemiology, vol. 24, no. 3, pp. 395–400, 2013. View at Publisher · View at Google Scholar · View at Scopus
  57. J. L. Gardy, J. C. Johnston, S. J. H. Sui et al., “Whole-genome sequencing and social-network analysis of a tuberculosis outbreak,” The New England Journal of Medicine, vol. 364, no. 8, pp. 730–739, 2011. View at Publisher · View at Google Scholar · View at Scopus
  58. C. Colijn, T. Cohen, and M. Murray, “Latent coinfection and the maintenance of strain diversity,” Bulletin of Mathematical Biology, vol. 71, no. 1, pp. 247–263, 2009. View at Publisher · View at Google Scholar · View at MathSciNet · View at Scopus
  59. T. Cohen, P. D. van Helden, D. Wilson et al., “Mixed-strain Mycobacterium tuberculosis infections and the implications for tuberculosis treatment and control,” Clinical Microbiology Reviews, vol. 25, no. 4, pp. 708–719, 2012. View at Publisher · View at Google Scholar · View at Scopus
  60. T. Cohen and M. Murray, “Modeling epidemics of multidrug-resistant M. tuberculosis of heterogeneous fitness,” Nature Medicine, vol. 10, no. 10, pp. 1117–1121, 2004. View at Publisher · View at Google Scholar · View at Scopus
  61. B. R. Levin, V. Perrot, and N. Walker, “Compensatory mutations, antibiotic resistance and the population genetics of adaptive evolution in bacteria,” Genetics, vol. 154, no. 3, pp. 985–997, 2000. View at Google Scholar · View at Scopus
  62. G. Brandis, M. Wrande, L. Liljas, and D. Hughes, “Fitness-compensatory mutations in rifampicin-resistant RNA polymerase,” Molecular Microbiology, vol. 85, no. 1, pp. 142–151, 2012. View at Publisher · View at Google Scholar · View at Scopus